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Introduction
Parkinson’s disease (PD) is a very common movement dis­
order characterized by dopaminergic neuronal loss. The major­
ity of PD cases are sporadic; however, the discovery of genes 
linked to rare familial forms of this disease has provided   
important insight into the molecular mechanisms of disease 
pathogenesis (Moore et al., 2005; Hardy et al., 2006). In 2000, 
we  and  others  found  that  dysfunction  of  an  E3  ubiquitin 
ligase (Imai et al., 2000; Shimura et al., 2000; Zhang et al., 
2000)  termed  Parkin  causes  autosomal  recessive  juvenile 
Parkinsonism (Kitada et al., 1998). Since then, a multitude 
of papers have been published, but the mechanism by which 
dysfunction of Parkin causes autosomal recessive juvenile 
Parkinsonism  has  largely  remained  obscure,  and  claims  of 
pathogenicity remain controversial (Lim, 2007; Matsuda and 
Tanaka,  2010).  In  addition,  PINK1  (PTEN-induced  putative 
kinase 1) was identified in 2004 as the gene responsible for 
another form of early­onset PD (Valente et al., 2004). PINK1   
functions in mitochondrial maintenance, suggesting that mito­
chondrial integrity is another key factor in disease patho­
genesis (Dodson and Guo, 2007; Schapira, 2008). Intriguingly, 
genetic studies using Drosophila melanogaster revealed that 
PINK1 and Parkin function in the same pathway, with PINK1 
functioning upstream of Parkin (Clark et al., 2006; Park et al., 
2006; Yang et al., 2006). Little is known about how PINK1 
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Figure 1.  Mitochondrial localization of Parkin is etiologically important. (A) HeLa cells expressing HA-Parkin were treated with CCCP or DMSO (control) 
and then immunostained with the indicated antibodies. (B) HeLa cells stably expressing HA-Parkin or intact SH-SY5Y cells were treated with CCCP or DMSO 
and subjected to fractionation experiments. I, C, and M indicate input, cytosol-rich supernatant, and mitochondria-rich membrane pellet, respectively.   
(C) Schematic diagram of disease-relevant mutants of Parkin used in this study. IBR, in between RING; Ubl, ubiquitin like. (D) Polarized mitochondria stained 
with MitoTracker red (red arrowheads) were not labeled by Parkin. In contrast, damaged mitochondria marked by Parkin (green arrowheads) were not 
stained with MitoTracker red. (E) HeLa cells expressing HA-Parkin with various pathogenic mutations were treated with CCCP, followed by immunocyto-
chemistry. (A, D, and E) Higher magnification views of the boxed areas are shown in the insets. (F) Parkin colocalization with mitochondria was analyzed 
in >100 cells per mutation. Example figures indicative of robust colocalization (counted as 1), weak colocalization (counted as 0.5), and no colocalization 
(counted as 0) are shown. Error bars represent the mean ± SD values of at least three experiments. Bars: (A, E, and F) 10 µm; (D) 30 µm.
 
regulates Parkin, and our knowledge, especially in mammals, 
of their relationship is limited. In this study, we describe the 
mechanism underlying the functional interplay between ubiq­
uitylation catalyzed by Parkin and mitochondrial quality con­
trol regulated by PINK1.
Results and discussion
Parkin localizes to and ubiquitylates 
mitochondria with low membrane potential
We initially sought to study the subcellular localization and 
E3 activity of Parkin using HeLa cells, which reportedly lack 
a functional Parkin gene (Denison et al., 2003). In support 
of that study, we found that endogenous Parkin was barely 
detectable in HeLa cells even when PRK8, the best­characterized   
specific anti­Parkin antibody (Pawlyk et al., 2003), was used 
(Fig. S1 A). Consequently, HA­Parkin was exogenously intro­
duced into HeLa cells. Under steady­state conditions, HA­
Parkin was diffusely localized throughout the cytosol and did 
not  overlap  with  mitochondria,  whereas  Parkin  was  rapidly 
recruited to the mitochondria when HeLa cells were treated 
with  the  mitochondrial  uncoupler  CCCP  (carbonyl  cyanide 
m­chlorophenylhydrazone; Fig. 1 A), as reported by Narendra 
et al. (2008). Next we tried to confirm the redistribution of 
Parkin from the cytoplasm to the mitochondria using a bio­
chemical approach. In fractionation experiments, detection 
of Parkin in the mitochondria­rich fraction was faint, probably 
because Parkin was weakly associated with the mitochondria 
and thus unstable during fractionation. Inclusion of the cross­
linker DSP (dithiobis[succinimidyl propionate]) significantly 
strengthened the signal and further confirmed redistribution   
of exogenous (Fig. 1 B, left) and endogenous (Fig. 1 B, right)   
Parkin from the cytoplasm to a mitochondria­enriched frac­
tion. (Note that endogenous Parkin in SH­SY5Y cells is detect­
able as a doublet, which is consistent with a previous study 
[Pawlyk et al., 2003].) To more convincingly demonstrate that 
Parkin  is  selectively  recruited  to  depolarized  mitochondria, 
we  used  MitoTracker  red  CMXRos,  which  accumulates  in 
mitochondria with an intact membrane potential. Incomplete 
treatment with CCCP can generate cells in which healthy and 
damaged mitochondria coexist. Under these conditions, signals of 
Parkin and MitoTracker were mutually exclusive, and Parkin 
selectively localized on mitochondria with lower MitoTracker 
red staining (Fig. 1 D), indicating that Parkin was selectively tar­
geted to mitochondria whose membrane potential had been lost.
Subsequently, we performed immunofluorescence stain­
ing using an antiubiquitin antibody. Under normal conditions, 
the ubiquitin signal was spread throughout the cell. In contrast, 
when  cells  were  treated  with  CCCP,  the  ubiquitin  signal 
was  concentrated  in  the  mitochondria  (Fig.  2, A  and  B). 
Mitochondrial ubiquitylation was only observed in Parkin­
expressing  cells  (Fig.  2 A  and  Fig.  S1  B)  and  disappeared 
when Parkin mutants deficient in E3 activity (T415N and 
G430D) were introduced (Fig. 2 A). Triple staining using 
mitochondria­targeting GFP (Mt­GFP), anti­Parkin, and anti­
ubiquitin antibodies further confirmed the colocalization of 
Parkin, ubiquitin, and mitochondria after CCCP treatment 
(Fig. 2 C). Staining with single antibodies or Mt­GFP alone 
indicated that the aforementioned merged data were not de­
rived from channel cross talk (Fig. S1, C and D). These results 
demonstrate  that  Parkin  ubiquitylates  mitochondria  in  re­
sponse to a reduction in mitochondrial membrane potential.
Disease-relevant mutations of Parkin 
impair mitochondrial localization
To confirm that translocation of Parkin to depolarized mito­
chondria is etiologically important, we selected nine patho­
genic  mutations  and  examined  their  subcellular  localization 
(Fig. 1 C). In vitro experiments have previously shown that two 
of the mutations (T415N and G430D) in the RING2 domain 
abolish E3 activity of Parkin, whereas E3 activity is unaffected by 
the other mutations (Hampe et al., 2006; Matsuda et al., 2006).   
These mutants were serially introduced into HeLa cells, fol­
lowed  by  CCCP  treatment,  and  their  subcellular  localization 
was examined. Parkin with the D280N or G328E mutation in 
RING1 or the IBR (in between RING) domain, respectively, 
was recruited to the mitochondria in a manner similar to wild­
type Parkin (Fig. 1, E and F). In contrast, the other pathogenic 
mutations altered to some degree the mitochondrial localiza­
tion of Parkin; in particular, the K161N, K211N, and T240R 
mutations, which lie in or near the RING0 domain in the linker 
region (Hristova et al., 2009), severely compromised the mito­
chondrial localization of Parkin (Fig. 1, E and F). The afore­
mentioned  results  suggest  that  mitochondrial  localization 
of Parkin is pathologically significant and that the RING0 
domain is important for the translocation of Parkin to the 
damaged mitochondria.
Parkin exerts E3 activity only  
when the mitochondrial membrane  
potential decreases
As shown in Fig. 2 C and Fig. S1 B, mitochondrial ubiqui­
tylation was dependent on Parkin translocation to the mito­
chondria. Thus, we tried to determine whether the subcellular 
localization  of  Parkin  modulates  its  E3  activity. To  address 
this issue, we monitored the E3 activity of Parkin using an JCB • VOLUME 189 • NUMBER 2 • 2010   214
Figure 2.  Parkin exerts E3 activity only when the mitochondrial membrane potential is decreased. (A) HeLa cells expressing wild-type Parkin or   
E3-inactivating mutations were treated with CCCP and then immunostained with the indicated antibodies. When E3-inactivating mutations were introduced into 
Parkin, the mitochondrial ubiquitylation signal disappeared. (B and C) HeLa cells expressing HA-Parkin (B) or expressing both Mt-GFP and HA-Parkin (C)   215 PINK1 recruits Parkin to damaged mitochondria • Matsuda et al.
were treated with CCCP or DMSO (control) and then immunostained with the indicated antibodies. (D) Localization of GFP-Parkin to the mitochondria 
after CCCP treatment. (A–D) Higher magnification views of the boxed areas are shown in the insets. (E) HeLa cell lysates expressing GFP-Parkin were 
immunoprecipitated by anti-GFP antibody, followed by immunoblotting with the indicated antibodies. (F) Straight immunoblotting of HA- and GFP-Parkin 
in the absence or presence of CCCP. Note the slower migrating ladders derived from ubiquitylation (Ub) in only the GFP-Parkin with CCCP lane. (G) GFP-
Parkin–expressing HeLa cells with various pathogenic mutations (Fig. 1 C) were treated with CCCP and subjected to immunoblotting. Asterisks show ubiq-
uitylation of GFP-Parkin. Vertical black lines indicate that intervening lanes have been spliced out. IB, immunoblot; IP, immunoprecipitation. Bars, 10 µm.
 
artificial substrate fused to Parkin. In vitro experiments have 
shown  that  Parkin  can  ubiquitylate  an  N­terminally  fused 
lysine­rich  protein  as  a  pseudosubstrate  (Matsuda  et  al., 
2006). Similar ubiquitylation of pseudosubstrates even in the 
cytoplasm under normal conditions in vivo would be evidence 
that the E3 activity is constitutive; otherwise, E3 activity of 
Parkin is dependent on mitochondrial retrieval. A GFP tag is   
lysine rich and thus a good candidate for an in vivo pseudo­
substrate, whereas an HA tag possesses no lysine residues and   
thus cannot function as a pseudosubstrate. GFP­ and HA­
Parkin expressed in HeLa cells treated with CCCP were both 
recruited to damaged mitochondria (Figs. 1 A and 2 D), but 
interestingly, a higher molecular mass population of only GFP­
Parkin was observed (Fig. 2 F). Immunoprecipitation experi­
ments demonstrated that GFP­Parkin was indeed ubiquitylated 
(Fig. 2 E). This was not based on autoubiquitylation of Parkin 
itself  because  mitochondria­associated  HA­Parkin  did  not 
undergo ubiquitylation after CCCP treatment (Fig. 2 F and not 
depicted). Moreover, ubiquitylation of GFP­Parkin was absent 
in the T415N and G430D mutants, which lack E3 activities, 
suggesting that ubiquitylation of GFP­Parkin is not derived 
from other E3s (Fig. 2 G). The K161N and K211N mutants 
that impaired mitochondrial localization also inhibited ubiqui­
tylation of GFP­Parkin (Fig. 2 G). Collectively, the aforemen­
tioned results indicate that Parkin ubiquitylates fused GFP only 
when  it  is  retrieved  to  the  mitochondria,  suggesting  that  the 
latent E3 activity of Parkin is dependent on decreased mito­
chondrial membrane potential.
PINK1 localization is stabilized by  
damaged mitochondria
Recessive mutations in the human PINK1 gene are also the cause 
of autosomal recessive early­onset PD (Valente et al., 2004). We 
next examined whether the subcellular localization of PINK1 
was affected by mitochondrial membrane potential. As reported 
previously (Valente et al., 2004; Beilina et al., 2005; Takatori et al.,   
2008), N­terminal Myc– or N­terminal Flag–tagged PINK1 
clearly localized to the mitochondria, whereas C­terminal Flag– 
or C­terminal V5–tagged PINK1 mainly localized to the cyto­
plasm (Fig. 3 A and not depicted). Exogenous nontagged PINK1 
also  localized  to  the  cytoplasm  under  steady­state  conditions 
(Fig. 3 B), suggesting that mitochondrial localization of PINK1 is 
an artifact of the N­terminal epitope. More importantly, similar 
to Parkin, untagged PINK1 and C­terminal Flag– or C­terminal 
V5–tagged PINK1 localized to the mitochondria after CCCP 
treatment (Fig. 3, A and B; and not depicted). These results sug­
gest that the subcellular localization of PINK1 is also regulated 
by the mitochondrial membrane potential.
We  next  sought  to  determine  the  subcellular  localization 
of  endogenous  PINK1.  Immunocytochemical  experiments 
showed, as reported previously (Zhou et al., 2008), that the 
endogenous PINK1 signal was barely detectable in HeLa cells 
under steady­state conditions. However, a decrease in mitochon­
drial membrane potential resulted in a mitochondria­associated   
PINK1 signal (Fig. 3, C and D). We found that CCCP treat­
ment  promoted  the  gradual  accumulation  of  endogenous 
PINK1 in immunoblots as well (Fig. 3 E) and the presence of 
endogenous PINK1 in a mitochondria­enriched fraction (Fig. 3 F). 
More importantly, when CCCP was washed out, the accumu­
lated endogenous PINK1 rapidly disappeared (within 30 min) 
both in the presence and absence of cycloheximide (Fig. 3 G 
and not depicted). Moreover, the N­terminal 34 aa of PINK1 
sufficiently recruited GFP to the mitochondria even in the ab­
sence of CCCP (Fig. 3 H). These results support the hypothesis 
in which PINK1 is constantly transported to the mitochondria 
but  is  rapidly  degraded  in  a  membrane  potential–dependent 
manner. We speculate that PINK1 is stabilized by a decrease 
in mitochondrial membrane potential and, as a result, accumu­
lates in depolarized mitochondria.
PINK1 normally exists as either a long (60 kD) or a 
short (50 kD) protein. Because the canonical mitochondria­
targeting signal (matrix­targeting signal) is cleaved after import 
into the mitochondria, the long form has been designated as 
the precursor and the short form as the mature PINK1 (Beilina 
et al., 2005; Silvestri et al., 2005). The short (processed) form 
of PINK1 was clearly detected when untagged PINK1 was over­
expressed (Fig. 3 E, sixth lane); however, this form of endog­
enous PINK1 was rarely detectable after CCCP treatment 
(Fig. 3 E, the first through the fifth lanes). Our subcellular local­
ization study of endogenous PINK1 after CCCP treatment 
showed that the long form was recovered in the mitochondrial 
fraction (Fig. 3 F), suggesting that it is not the preimport pre­
cursor form. Moreover, by monitoring the degradation process 
of PINK1 after recovery of membrane potential, we realized 
that the short form of PINK1 transiently appeared soon after 
CCCP was washed out and then later disappeared (Fig. 3 G), 
suggesting that the processed form of PINK1 is an intermedi­
ate in membrane potential–dependent degradation. In conclu­
sion, these results imply that PINK1 cleavage dose not reflect 
a canonical maturation process accompanying mitochondrial 
import as initially thought.
PINK1 retrieves Parkin from the cytoplasm 
to the mitochondria
Because previous studies revealed that PINK1 functions upstream 
of Parkin (Clark et al., 2006; Park et al., 2006; Yang et al., 
2006; Exner et al., 2007), we next examined the potential role 
of PINK1 in the mitochondrial recruitment of Parkin. To obtain 
clear­cut conclusions, we set up our experimental system using 
mouse embryonic fibroblasts (MEFs) derived from control JCB • VOLUME 189 • NUMBER 2 • 2010   216
Figure 3.  PINK1 is constitutively degraded in a mitochondrial membrane potential–dependent manner and localizes to depolarized mitochondria. (A) The 
number of HeLa cells with N-terminal– or C-terminal–tagged PINK1 localized to the mitochondria was counted in >100 cells. (B and C) Exogenous non-
tagged PINK1 (B) or endogenous PINK1 (C) in HeLa cells was immunostained with the indicated antibodies. (D) The number of HeLa cells with endogenous 
PINK1 localized to the mitochondria was counted as in A. (A and D) Error bars represent the mean ± SD values of least three experiments. (E) Endogenous 
PINK1 gradually accumulated after CCCP treatment. The first through the fifth lanes show endogenous PINK1, and the sixth lane shows overexpressed 
untagged PINK1. Note that the asterisk indicates a cross-reacting band because it was not affected by overproduction of untagged PINK1. (F) Subcellular 
fractionation of endogenous PINK1. Intact SH-SY5Y cells were treated with CCCP or DMSO and subjected to fractionation experiments (same sample as 217 PINK1 recruits Parkin to damaged mitochondria • Matsuda et al.
Fig. 1 B). I, C, and M indicate input, cytosol-rich supernatant, and the mitochondria-rich membrane pellet, respectively. (G) HeLa cells were treated with 
CCCP and cycloheximide as depicted, followed by immunoblotting with the indicated antibodies. LDH, lactate dehydrogenase. (F and G) Asterisks indicate 
a cross-reacting band. (H) N-terminal 34 aa of PINK1 recruited GFP to the mitochondria both in the absence and presence of CCCP. The top panel shows 
control HeLa cells expressing only GFP. (B, C, and H) Higher magnification views of the boxed areas are shown in the insets. Bars, 10 µm.
 
(PINK1
+/+) or PINK1 knockout (PINK1
/) mouse (Gautier et al.,   
2008). Endogenous Parkin is undetectable in MEFs (Fig. S1 A); 
consequently, HA­ or GFP­Parkin was introduced into these 
cells by retroviral transfection (Kitamura et al., 2003). In control   
MEFs (PINK1
+/+), Parkin was selectively recruited to the mito­
chondria after CCCP treatment (Fig. 4 A) and subsequently 
resulted in the disappearance of the mitochondria (Fig. 4,   
D and  E). This  mitochondrial  clearance  was  considerably 
impeded by Atg7 (essential gene for autophagy) knockout 
(Fig. S2; Komatsu et al., 2005), suggesting that Parkin degrades 
mitochondria by selective autophagy as reported previously   
(Narendra  et  al.,  2008).  In  sharp  contrast,  Parkin  was  not   
Figure 4.  PINK1 recruits cytoplasmic Parkin to damaged mitochondria. (A) PINK1 knockout (PINK1
/) or control (PINK1
+/+) MEFs were transfected with 
HA-Parkin, treated with CCCP, and subjected to immunocytochemistry with the indicated antibodies. Higher magnification views of the boxed areas are 
shown in the insets. (B) The number of MEFs with Parkin localized to the mitochondria was counted as in Fig. 3 A. (C and D) Neither activation of Parkin 
nor mitochondrial degradation was observed in PINK1
/ MEFs. MEFs stably expressing GFP-Parkin were treated with CCCP for 4 h and subjected to 
immunoblotting (C) or for 24 h, followed by immunocytochemistry (D). IB, immunoblot; Ub, ubiquitylation. (E) The number of MEFs without anti-Tom20 
antibody–detectable mitochondria was counted as in Fig. 3 A. In the example figure (left), blue arrowheads indicate cells without anti-Tom20 antibody– 
detectable mitochondria, and red arrowheads indicate cells harboring anti-Tom20 antibody–detectable mitochondria. (B and E) Error bars represent the 
mean ± SD values of least three experiments. Bars: (A) 10 µm; (D) 50 µm; (E) 150 µm.JCB • VOLUME 189 • NUMBER 2 • 2010   218
Figure 5.  Kinase activity and mitochondrial targeting of PINK1 is imperative for mitochondrial localization of Parkin. (A) Schematic depiction of patho-
genic and deletion mutants of PINK1 used in this study. MTS, mitochondria-targeting sequence; TMD, transmembrane domain. (B) Subcellular localization 
of Parkin in PINK1
/ cells complemented by various pathogenic and deletion mutants of PINK1-Flag. Cells were treated with CCCP. Higher magnification 
views of the boxed areas are shown in the insets. (C) The number of cells with Parkin-positive mitochondria was counted as in Fig. 3 A. Error bars represent 
the mean ± SD values of least three experiments. (D) PINK1
/ MEFs complemented by various PINK1 mutants were treated with CCCP and subjected to 
immunoblotting using anti-Parkin or anti-Flag (tag of PINK1) antibodies. IB, immunoblot; Ub, ubiquitylation. Bars, 10 µm.219 PINK1 recruits Parkin to damaged mitochondria • Matsuda et al.
is specifically linked to a decrease in membrane potential, 
(c) under steady­state conditions, the E3 activity of Parkin is 
repressed in the cytoplasm but is liberated by PINK1­dependent 
mitochondrial  localization,  and  (d)  the  aforementioned  phe­
nomena are presumably etiologically important in part because 
they were impeded for the most part by disease­linked muta­
tions of PINK1 or Parkin. We believe that these results provide 
solid insight into the molecular mechanisms of PD pathogenesis 
not only for familial forms caused by Parkin and PINK1 muta­
tions but also major sporadic forms of PD.
Materials and methods
Cell culture and transfection
MEFs derived from embryonic day 12.5 embryos of PINK1 knockout mice 
(provided by J. Shen, Harvard Medical School, Boston, MA) were mechani-
cally dispersed by repeated passage through a P1000 pipette tip and plated 
with MEF media containing DME, 10% FCS, -mercaptoethanol (Sigma- 
Aldrich), 1× nonessential amino acids, and 1 mM l-glutamine. Various sta-
ble transformants of MEFs were established by infecting MEFs with recombi-
nant retroviruses. HA-Parkin, GFP-Parkin, PINK1 (provided by Y. Nakamura,   
T. Iwatsubo, and S. Takatori, University of Tokyo, Bunkyo-ku, Tokyo, Japan), 
or various PINK1 mutants were cloned into a pMXs-puro vector. Retrovirus 
packaging cells, PLAT-E (provided by T. Kitamura, University of Tokyo; 
Kitamura et al., 2003), were transfected with the aforementioned vectors 
and were cultured at 37°C for 24 h. After changing the medium, cells were 
further incubated at 37°C for 24 h, and the viral supernatant was collected 
and used for infection. MEFs were plated on 35-mm dishes at 24 h before 
infection, and the medium was replaced with the aforementioned undiluted 
viral supernatant with 8 µg/ml polybrene (Sigma-Aldrich). 2 d later, trans-
formants were selected by the medium containing 10 µg/ml puromycin.
Cell fractionation and immunoprecipitation
To depolarize the mitochondria, HeLa and SH-SY5Y cells were treated with 
10 µM CCCP, and MEFs were treated with 30 µM CCCP. For fractionation 
experiments, HeLa and SH-SY5Y cells were treated with CCCP for 1–5 h   
and subsequently treated with 1 mM DSP (Thermo Fisher Scientific) in PBS 
for 1 h on ice, inactivated by 10 mM glycine in PBS three times, and 
suspended in chappell-perry buffer (0.15 M KCl, 20 mM Hepes-NaOH,   
pH 8.1, 5 mM MgCl2, and protease and phosphatase inhibitor [Roche]). 
Cells were disrupted by five passages through a 25-gauge needle (with 
1-ml  syringe),  debris  was  removed  by  centrifugation  at  1,000  g  for   
7 min, and the supernatant was subjected to 10,000 g for 10 min to 
separate  the  mitochondria-rich  fraction  from  the  cytosol-rich  fraction. 
Immunoblotting  and  immunoprecipitation  were  performed  by  conven-
tional methods. To detect the ubiquitylation of GFP-Parkin, the cell lysate 
of HeLa cells (10 µM CCCP for 1 h) or MEFs (30 µM CCCP for 3 h) was 
collected in the presence of 10 mM N-ethylmaleimide to protect ubiquity-
lated Parkin from deubiquitylation enzymes. To monitor the degradation 
of endogenous PINK1, HeLa cells were treated with 10 µM CCCP and 
50 µg/ml cycloheximide as depicted in Fig. 3 G and were subjected 
to immunoblotting.
Immunocytochemistry
To depolarize the mitochondria, HeLa cells (provided by A. Tanaka and   
R. Youle, National Institutes of Health, Bethesda, MD) were treated with 
10 µM CCCP for 1 h (exogenous Parkin and PINK1) or 5 h (endogenous 
PINK1), and MEFs were treated with 30 µM CCCP for 3–4 h (Figs. 4 A 
and 5 B; and Fig. S3 B) or 24 h (Fig. 4 D and Fig. S2 A). For immunofluores-
cence  experiments,  cells  were  fixed  with  4%  paraformaldehyde,  per-
meabilized with 50 µg/ml digitonin, and stained with primary antibodies 
described in the next section and with the following secondary anti-
bodies: mouse and/or rabbit Alexa Fluor 488, 568, and 647 (Invitrogen).   
N-terminal 34 aa of PINK1 were fused to GFP to stain mitochondria in the 
triple staining experiments. To monitor the mitochondrial membrane poten-
tial, MEFs were treated with 50 nM MitoTracker red CMXRos (Invitrogen) 
for 15 min, washed three times, and incubated for an additional 10 min 
before fixation, as reported previously (Narendra et al., 2008). Cells were 
imaged  using  a  laser-scanning  microscope  (LSM510  META;  Carl  Zeiss, 
Inc.) with a Plan-Apochromat 63× NA 1.4 oil differential interference 
contrast objective lens. Image contrast and brightness were adjusted in 
Photoshop (Adobe).
translocated to the mitochondria in PINK1 knockout (PINK1
/) 
MEFs after CCCP treatment (Fig. 4, A and B). Subsequent 
activation of Parkin and mitochondrial degradation were also 
completely impeded (Fig. 4, C–E). To exclude the possible role 
of retroviral integration of Parkin in the aforementioned pheno­
type, we checked whether reintroduction of PINK1 rescued this 
phenotype. Untagged or C­terminal Flag–tagged PINK1 com­
plemented the mislocalization of Parkin in PINK1
/ MEFs 
(Fig. 5, B and C; and not depicted), confirming that the afore­
mentioned defects were caused by the loss of PINK1.
To examine whether pathogenic mutations of PINK1 
affect its mitochondrial localization, we expressed PINK1 
mutants harboring the missense mutations E240K and G309D, 
or a CAA nucleotide insertion behind C1602 (referred to here­
after as 1602­insert) in PINK1
/ MEFs. Similar to wild­type 
PINK1,  these  PINK1  mutants  colocalized  with  mitochondria 
after CCCP treatment (Fig. S3). Next, GFP­Parkin was intro­
duced into these cells to examine whether pathogenic mutations 
of PINK1 affect the mitochondrial localization and activation of 
Parkin. The E240K and G309D mutants restored the mitochon­
drial localization and activation of Parkin as well as wild­type 
PINK1, whereas recruitment of Parkin to the mitochondria by 
the 1602­insert mutant was abolished (Fig. 5, B–D), suggesting 
that the pathology of this PINK1 mutation is mislocalization 
and consequent inactivation of Parkin.
Mitochondrial localization and kinase activity 
of PINK1 are essential for translocation of 
Parkin to damaged mitochondria
Finally,  we  investigated  the  role  of  various  PINK1  domains 
(Fig. 5 A) in the mitochondrial recruitment of Parkin. PINK1 
is composed of an atypical N­terminal mitochondrial localiza­
tion signal and transmembrane domain, a kinase domain in the 
middle, and a conserved C­terminal domain (Zhou et al., 2008). 
Deletion of the N­terminal 91 aa abolished the mitochondrial 
localization of PINK1 (Zhou et al., 2008). We also confirmed 
that the ∆N91 and ∆N155 mutants did not target to the mito­
chondria even after CCCP treatment (Fig. S3). We also gener­
ated a mutant containing the triple K219A, D362A, and D384A 
mutations that abolish kinase activity (Beilina et al., 2005) and 
a C­terminal domain deletion mutant associated with PINK1 
dysfunction (Sim et al., 2006; Yang et al., 2006). The kinase­
dead and ∆C72 mutants of PINK1 colocalized with damaged 
mitochondria similar to wild type (Fig. S3). When introduced 
into PINK1
/ cells harboring GFP­Parkin, the mutants were 
unable to complement the mislocalization and inactivation of 
Parkin (Fig. 5, B–D), even though the mutant PINK1 proteins 
were expressed (Fig. 5 D and Fig. S3). These results indicate 
that the kinase activity and mitochondrial targeting of PINK1 
are essential for the mitochondrial recruitment of Parkin.
Conclusion
In  summary,  we  have  shown  that  (a)  PINK1  is  a  Parkin­
recruitment factor that recruits Parkin from the cytoplasm to dam­
aged mitochondria in a membrane potential–dependent manner 
for mitochondrial degradation, (b) endogenous PINK1 is con­
stitutively degraded at the mitochondria, but its localization   JCB • VOLUME 189 • NUMBER 2 • 2010   220
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